CHARLES JOSEPH BECK MD
Prescription History 1932174521
Ophthalmology - Retina Specialist in Wichita, KS


Quality Rating: 0 out of 100 score

NPI Status: Active since February 17, 2006

Contact Information

7717 E 29TH ST N STE 100
WICHITA, KS
ZIP 67226
Phone: (316) 712-4970
Fax: (316) 712-4987

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CHARLES JOSEPH BECK MD, an active Retina Specialist specialist practicing in Wichita, KS. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,017 documented patient claims. Among these therapy options, the most frequently utilized medication is Dorzolamide Hcl, which accounts for 292 claims alone.


Betaxolol Hcl

Generic Formulation: Betaxolol HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 19
30-Day Fills 47.2
Days Supply 1,415
KS State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills72.3
Peer Average Days Supply2,121
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.8% less volume than the regional standard for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $939.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$49.42

State Avg Cost Per Claim

$54.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. Betaxolol belongs to a class of drugs known as beta blockers and works by decreasing the amount of fluid that is made within the eye.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 159
30-Day Fills 352.9
Days Supply 10,524
KS State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills69.1
Peer Average Days Supply1,960
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 278.6% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,982.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.47

State Avg Cost Per Claim

$33.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Diclofenac Sodium

Generic Formulation: Diclofenac SodiumSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 62
30-Day Fills 96.7
Days Supply 2,832
KS State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills49.0
Peer Average Days Supply1,099
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 59.0% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $761.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.29

State Avg Cost Per Claim

$29.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.

Therapeutic Applications

See also Warning section. This medication is used to relieve joint pain from arthritis. Diclofenac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 292
30-Day Fills 827.0
Days Supply 24,770
KS State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills76.7
Peer Average Days Supply2,283
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 630.0% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,916.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.69

State Avg Cost Per Claim

$24.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 133
30-Day Fills 181.7
Days Supply 4,961
KS State Average Benchmarks
Peer Average Claims116.0
Peer Average 30-Day Fills189.2
Peer Average Days Supply5,331
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,441.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.84

State Avg Cost Per Claim

$17.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Moxifloxacin

Generic Formulation: Moxifloxacin HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 260
30-Day Fills 260.8
Days Supply 3,578
KS State Average Benchmarks
Peer Average Claims85.0
Peer Average 30-Day Fills85.8
Peer Average Days Supply1,290
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 205.9% higher than the standard regional baseline profile for KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,047.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.80

State Avg Cost Per Claim

$35.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.

Therapeutic Applications

This medication is a quinolone antibiotic used for eye infections.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 31
30-Day Fills 36.7
Days Supply 863
KS State Average Benchmarks
Peer Average Claims111.0
Peer Average 30-Day Fills139.3
Peer Average Days Supply3,533
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.1% less volume than the regional standard for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,061.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.24

State Avg Cost Per Claim

$46.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Simbrinza

Generic Formulation: Brinzolamide/Brimonidine TartSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 18
30-Day Fills 42.4
Days Supply 1,270
KS State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills39.9
Peer Average Days Supply1,149
Conservative Utilization

This provider writes prescriptions for this formulation 30.8% less frequently than the standard regional baseline metric for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,836.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$213.14

State Avg Cost Per Claim

$247.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two medications used to treat high pressure in the eye due to glaucoma (open-angle glaucoma-type) or a certain other eye disease (ocular hypertension). Lowering high pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This product contains brinzolamide and brimonidine. These two medications work together to decrease the amount of fluid within the eye. Brinzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. Brimonidine belongs to a class of drugs known as alpha agonists. This product is not recommended for use in children younger than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 43
30-Day Fills 74.5
Days Supply 2,223
KS State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills113.1
Peer Average Days Supply3,315
Conservative Utilization

This provider writes prescriptions for this formulation 27.1% less frequently than the standard regional baseline metric for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $281.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.54

State Avg Cost Per Claim

$14.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CHARLES JOSEPH BECK MD provides transparency into local medical care patterns within Wichita, KS.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Retina Specialist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.